BR112015026410A2 - derivados de dolastatina 10 e auristatinas - Google Patents

derivados de dolastatina 10 e auristatinas

Info

Publication number
BR112015026410A2
BR112015026410A2 BR112015026410A BR112015026410A BR112015026410A2 BR 112015026410 A2 BR112015026410 A2 BR 112015026410A2 BR 112015026410 A BR112015026410 A BR 112015026410A BR 112015026410 A BR112015026410 A BR 112015026410A BR 112015026410 A2 BR112015026410 A2 BR 112015026410A2
Authority
BR
Brazil
Prior art keywords
auristatins
dolastatin
derivatives
alkyl
alkyl group
Prior art date
Application number
BR112015026410A
Other languages
English (en)
Other versions
BR112015026410B1 (pt
Inventor
Rilatt Ian
Lamothe Marie
Perez Michel
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112015026410A2 publication Critical patent/BR112015026410A2/pt
Publication of BR112015026410B1 publication Critical patent/BR112015026410B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Abstract

resumo patente de invenção: "derivados de dolastatina 10 e auristatinas". a presente invenção refere-se a um composto da seguinte fórmula (i): (i) onde: - r1 é h ou oh, - r2 é um grupo (c1-c6)alquila, cooh, coo-((c1-c6)alquila) ou tiazolila, - r3 é h ou um grupo (c1-c6)alquila, e - r4 é um grupo aril-(c1-c8)alquila substituído por um ou mais grupos escolhidos dentre grupos oh e nr9r10, ou um sal, hidrato ou solvato farmaceuticamente aceitável do mesmo, e seus empregos em particular para o tratamento de câncer, composições farmacêuticas contendo o mesmo e os métodos de preparação das mesmas.
BR112015026410-7A 2013-04-25 2014-04-25 Derivados de dolastatina 10 e auristatinas, seu uso, sua composição farmacêutica e seus métodos para preparação BR112015026410B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353793 2013-04-25
FR1353793A FR3005051A1 (fr) 2013-04-25 2013-04-25 Derives de la dolastatine 10 et d'auristatines
PCT/EP2014/058427 WO2014174064A1 (en) 2013-04-25 2014-04-25 Derivatives of dolastatin 10 and auristatins

Publications (2)

Publication Number Publication Date
BR112015026410A2 true BR112015026410A2 (pt) 2017-07-25
BR112015026410B1 BR112015026410B1 (pt) 2022-06-07

Family

ID=48782433

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112015026478A BR112015026478A2 (pt) 2013-04-25 2014-04-25 derivados de dolastatina 10 e auristatinas
BR112015026410-7A BR112015026410B1 (pt) 2013-04-25 2014-04-25 Derivados de dolastatina 10 e auristatinas, seu uso, sua composição farmacêutica e seus métodos para preparação
BR112015026565A BR112015026565A2 (pt) 2013-04-25 2014-04-25 derivados de dolastatina 10 e auristatinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112015026478A BR112015026478A2 (pt) 2013-04-25 2014-04-25 derivados de dolastatina 10 e auristatinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015026565A BR112015026565A2 (pt) 2013-04-25 2014-04-25 derivados de dolastatina 10 e auristatinas

Country Status (32)

Country Link
US (7) US20160068567A1 (pt)
EP (4) EP3388427B1 (pt)
JP (3) JP6606489B2 (pt)
KR (4) KR102368136B1 (pt)
CN (3) CN105408318A (pt)
AU (3) AU2014259427B2 (pt)
BR (3) BR112015026478A2 (pt)
CA (4) CA2910176C (pt)
CY (2) CY1119677T1 (pt)
DK (3) DK3388427T3 (pt)
ES (3) ES2654364T3 (pt)
FR (1) FR3005051A1 (pt)
HK (2) HK1215580A1 (pt)
HR (2) HRP20171977T1 (pt)
HU (3) HUE058167T2 (pt)
IL (1) IL242184A (pt)
LT (2) LT2989086T (pt)
MA (1) MA38583B1 (pt)
MX (3) MX2015014746A (pt)
MY (1) MY177702A (pt)
NO (1) NO2989088T3 (pt)
NZ (1) NZ714203A (pt)
PL (3) PL3388427T3 (pt)
PT (2) PT2989086T (pt)
RS (2) RS56717B1 (pt)
RU (3) RU2015146957A (pt)
SA (1) SA515370043B1 (pt)
SI (2) SI2989088T1 (pt)
TN (2) TN2015000445A1 (pt)
UA (1) UA115806C2 (pt)
WO (3) WO2014174062A1 (pt)
ZA (1) ZA201508545B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
PT3134124T (pt) 2014-04-25 2019-06-03 Pf Medicament Conjugado anticorpo-fármaco igf-1r e a sua utilização para o tratamento de cancro
ES2764110T3 (es) * 2014-04-25 2020-06-02 Pf Medicament Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
MX2018010128A (es) * 2016-02-26 2019-01-21 Jiangsu Hengrui Medicine Co Toxina nueva y metodo de preparacion de un intermediario de la misma.
HUE062120T2 (hu) * 2016-03-29 2023-09-28 Toray Industries Peptid-származék és alkalmazása
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) * 2016-08-18 2017-02-22 重庆大学 一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) * 2017-06-23 2017-11-07 华东师范大学 一种高立体选择性合成海兔毒素Dap片段的方法
CN111712511A (zh) * 2017-11-30 2020-09-25 森托瑞恩生物制药公司 澳瑞他汀e衍生物的白蛋白结合产物
AU2019350536A1 (en) 2018-09-27 2021-05-06 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
CN110724337B (zh) * 2019-10-16 2022-04-05 江苏德威新材料股份有限公司 一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173150C (en) * 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP3498289A1 (en) * 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CN102056626B (zh) * 2008-04-11 2016-07-06 西雅图遗传学公司 胰腺癌、卵巢癌和其它癌症的检测和治疗
CN102448486A (zh) * 2009-03-06 2012-05-09 艾更斯司股份有限公司 结合于24p4c12蛋白的抗体药物偶联物(adc)
JP5791707B2 (ja) * 2010-06-10 2015-10-07 シアトル ジェネティックス， インコーポレイテッド 新規アウリスタチン誘導体およびその使用
ES2553874T3 (es) * 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
WO2012059882A2 (en) * 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2829736C (en) * 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatins and use thereof
US20130122024A1 (en) * 2011-04-21 2013-05-16 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof
EP3470413A3 (en) * 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX371526B (es) * 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
DK2858676T3 (da) * 2012-06-07 2019-05-13 Ambrx Inc Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
KR102490719B1 (ko) * 2012-06-19 2023-01-19 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
US20150314007A1 (en) * 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
ES2764110T3 (es) * 2014-04-25 2020-06-02 Pf Medicament Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer

Also Published As

Publication number Publication date
EP2989087A1 (en) 2016-03-02
PL3388427T3 (pl) 2022-05-09
KR20210046871A (ko) 2021-04-28
EP2989086A1 (en) 2016-03-02
KR20160003003A (ko) 2016-01-08
AU2014259431B2 (en) 2017-02-02
DK3388427T3 (da) 2022-03-07
JP6017728B2 (ja) 2016-11-02
WO2014174064A1 (en) 2014-10-30
DK2989088T3 (en) 2017-12-18
BR112015026478A2 (pt) 2017-07-25
MX345126B (es) 2017-01-17
RS56717B1 (sr) 2018-03-30
RU2015149527A (ru) 2017-05-29
TN2015000439A1 (en) 2017-01-03
AU2014259427A1 (en) 2015-11-19
US20160068567A1 (en) 2016-03-10
CN105377834A (zh) 2016-03-02
JP6606489B2 (ja) 2019-11-13
US20160068566A1 (en) 2016-03-10
TN2015000445A1 (en) 2017-04-06
NO2989088T3 (pt) 2018-02-24
HUE058167T2 (hu) 2022-07-28
BR112015026410B1 (pt) 2022-06-07
CN105408318A (zh) 2016-03-16
HUE040431T2 (hu) 2019-03-28
WO2014174062A1 (en) 2014-10-30
PT2989088T (pt) 2018-01-03
JP2016519114A (ja) 2016-06-30
US20200010414A1 (en) 2020-01-09
IL242184A (en) 2017-09-28
US20160083420A1 (en) 2016-03-24
LT2989088T (lt) 2018-01-10
RS58161B1 (sr) 2019-03-29
WO2014174060A1 (en) 2014-10-30
DK2989086T3 (en) 2018-11-12
CA2910176C (en) 2021-11-09
MA38583B1 (fr) 2018-11-30
KR20160003734A (ko) 2016-01-11
KR102368136B1 (ko) 2022-02-25
HK1215867A1 (zh) 2016-09-23
EP3388427B1 (en) 2022-01-19
US20180222858A1 (en) 2018-08-09
CY1119677T1 (el) 2018-04-04
FR3005051A1 (fr) 2014-10-31
HRP20181890T1 (hr) 2019-01-11
EP2989086B1 (en) 2018-08-22
ZA201508545B (en) 2017-07-26
KR20160003735A (ko) 2016-01-11
KR101640361B1 (ko) 2016-07-15
RU2662951C2 (ru) 2018-07-31
PL2989088T3 (pl) 2018-03-30
MA38583A1 (fr) 2018-07-31
EP2989088B1 (en) 2017-09-27
JP2016520041A (ja) 2016-07-11
SI2989088T1 (en) 2018-02-28
HUE035180T2 (hu) 2018-05-02
CA2910178A1 (en) 2014-10-30
CN105377834B (zh) 2018-04-20
CA2910176A1 (en) 2014-10-30
NZ714203A (en) 2020-05-29
BR112015026565A2 (pt) 2017-07-25
CA2909126A1 (en) 2014-10-30
AU2014259427B2 (en) 2018-04-05
EP3388427A1 (en) 2018-10-17
LT2989086T (lt) 2018-11-26
KR102389167B1 (ko) 2022-04-20
ES2908224T3 (es) 2022-04-28
MX2015014831A (es) 2016-08-03
CA3130994A1 (en) 2014-10-30
UA115806C2 (uk) 2017-12-26
CY1120863T1 (el) 2019-12-11
PT2989086T (pt) 2018-11-29
PL2989086T3 (pl) 2019-02-28
HRP20171977T1 (hr) 2018-02-09
MY177702A (en) 2020-09-23
ES2693368T3 (es) 2018-12-11
HK1215580A1 (zh) 2016-09-02
CN105143199A (zh) 2015-12-09
MX2015014941A (es) 2016-03-07
AU2014259431A1 (en) 2015-12-03
RU2015147447A (ru) 2017-05-31
SA515370043B1 (ar) 2018-01-24
EP2989088A1 (en) 2016-03-02
AU2014259429A1 (en) 2015-11-12
ES2654364T3 (es) 2018-02-13
MX2015014746A (es) 2016-03-04
US20230002316A1 (en) 2023-01-05
RU2015146957A (ru) 2017-05-31
US20210107868A1 (en) 2021-04-15
JP2016519115A (ja) 2016-06-30
SI2989086T1 (sl) 2018-12-31

Similar Documents

Publication Publication Date Title
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
EA201690094A1 (ru) Ингибиторы syk
BR112014026643A2 (pt) derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
MD4659B1 (ro) Polimorf al inhibitorilor SYK
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
BR112015023448A2 (pt) compostos e composições para o tratamento de doenças parasíticas
BR112015028212A2 (pt) derivado de fenol e método de preparação e utilização dos mesmos na medicina
BR112018016932A2 (pt) processo para a preparação de ácido 4 -fenil -5 -alcoxicarbonil -2 -tiazol -2 -il -1,4 -diidropirimidin -6 -il[metil] -3 -oxo -5,6,8,8a -tetrahidro -1h -imidazo[1,5 -a]pirazin -2 -il] -carboxil acid
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
BR112013017520A2 (pt) composto bicíclico ou sal do mesmo
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112016011778A8 (pt) pirazol fluorofenila, seus usos, e composição farmacêutica
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.